140 related articles for article (PubMed ID: 31961035)
21. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure.
Barnes C; Rudzki Z; Ekert H
Haemophilia; 2000 Nov; 6(6):693-5. PubMed ID: 11122398
[TBL] [Abstract][Full Text] [Related]
22. Suppression of secondary antibody response by intravenous immunoglobulin and development of tolerance in a patient with haemophilia B and antibodies.
Nilsson IM; Sundqvist SB
Scand J Haematol Suppl; 1984; 40():203-6. PubMed ID: 6591389
[No Abstract] [Full Text] [Related]
23. Haemophilia B: Christmas disease.
Giangrande P
Expert Opin Pharmacother; 2005 Aug; 6(9):1517-24. PubMed ID: 16086639
[TBL] [Abstract][Full Text] [Related]
24. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.
Curry NS; Misbah SA; Giangrande PL; Keeling DM
Haemophilia; 2007 May; 13(3):328-30. PubMed ID: 17498084
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
Chitlur M; Warrier I; Rajpurkar M; Lusher JM
Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
[TBL] [Abstract][Full Text] [Related]
26. Development of an inhibitor in a child with severe hemophilia B: treatment with immunosuppression and an extended desensitization protocol.
Roberts JC; Jesudas R; Tarantino MD
Blood Coagul Fibrinolysis; 2019 Sep; 30(6):291-294. PubMed ID: 31259775
[TBL] [Abstract][Full Text] [Related]
27. Development of anaphylactic shock in haemophilia B patients with inhibitors.
Warrier I; Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S125-8. PubMed ID: 9819043
[TBL] [Abstract][Full Text] [Related]
28. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report.
Barnes C; Brewin T; Ekert H
Haemophilia; 2001 Jul; 7(4):439-40. PubMed ID: 11442653
[No Abstract] [Full Text] [Related]
29. Macrohematuria as initial presentation in a girl with factor VIII and factor IX inhibitors associated with systemic lupus erythematosus.
Shen CY; Fu LS; Lin HK; Han SM; Wang JD
J Pediatr Hematol Oncol; 2012 Nov; 34(8):e344-5. PubMed ID: 23018565
[TBL] [Abstract][Full Text] [Related]
30. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
31. Induced tolerance in hemophilia patients with antibodies against IX:C.
Hedner U; Nilsson IM
Acta Med Scand; 1983; 214(3):191-7. PubMed ID: 6660025
[TBL] [Abstract][Full Text] [Related]
32. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
Thorland EC; Drost JB; Lusher JM; Warrier I; Shapiro A; Koerper MA; Dimichele D; Westman J; Key NS; Sommer SS
Haemophilia; 1999 Mar; 5(2):101-5. PubMed ID: 10215957
[TBL] [Abstract][Full Text] [Related]
33. Arthroscopic synovectomy of the elbow covered with rFVIIa in a haemophilia B juvenile with inhibitor.
Shimada K; Takedani H; Inoue K; Yamasaki K
Haemophilia; 2012 Nov; 18(6):e414-6. PubMed ID: 22888990
[No Abstract] [Full Text] [Related]
34. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
Abshire T; Kenet G
Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
[TBL] [Abstract][Full Text] [Related]
35. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor.
Klarmann D; Martinez Saguer I; Funk MB; Knoefler R; von Hentig N; Heller C; Kreuz W
Haemophilia; 2008 Jan; 14(1):44-9. PubMed ID: 18081836
[TBL] [Abstract][Full Text] [Related]
36. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B.
Saini S; Croteau SE; Horling FM; Dunn AL
Haemophilia; 2019 Mar; 25(2):e126-e129. PubMed ID: 30817051
[No Abstract] [Full Text] [Related]
37. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
38. Inhibitors in haemophilia B: the Italian experience.
Castaman G; Bonetti E; Messina M; Morfini M; Rocino A; Scaraggi FA; Tagariello G;
Haemophilia; 2013 Sep; 19(5):686-90. PubMed ID: 23601006
[TBL] [Abstract][Full Text] [Related]
39. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
40. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
